REGENERON PHARMACEUTICALS INC

NASDAQ: REGN (Regeneron Pharmaceuticals, Inc.)

Kemas kini terakhir: 24 Jan, 6:27PM

753.55

-1.96 (-0.26%)

  • 1H -0.26%
  • 5H -1.19%
  • 1B -1.27%
  • 6B 31.85%
  • Tahun Ke Tarikh -2.93%
  • 1T 13.00%
  • 5T 53.42%
Penutupan Terdahulu 755.51
Buka 757.31
Jumlah Dagangan 676,321
Purata Dagangan (3B) 1,008,519
Modal Pasaran 79,866,830,848
Harga / Pendapatan (P/E TTM) 18.05
Harga / Pendapatan (P/E Ke hadapan) 16.86
Harga / Jualan (P/S) 5.61
Harga / Buku (P/B) 2.49
Julat 52 Minggu
476.49 (-36%) — 821.11 (8%)
Tarikh Pendapatan 30 Jan 2026
Hasil Dividen (DY TTM) 0.47%
Margin Keuntungan 31.94%
Margin Operasi (TTM) 19.94%
EPS Cair (TTM) 39.36
Pertumbuhan Hasil Suku Tahunan (YOY) -3.70%
Pertumbuhan Pendapatan Suku Tahunan (YOY) 12.00%
Jumlah Hutang/Ekuiti (D/E MRQ) 9.20%
Nisbah Semasa (MRQ) 4.93
Aliran Tunai Operasi (OCF TTM) 3.95 B
Aliran Tunai Bebas Leveraj (LFCF TTM) 2.08 B
Pulangan Atas Aset (ROA TTM) 6.91%
Pulangan Atas Ekuiti (ROE TTM) 15.96%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Menaik Bercampur
Biotechnology (Global) Menaik Bercampur
Stok Regeneron Pharmaceuticals, Inc. Menaik Menurun

AISkor Stockmoo

0.1
Konsensus Penganalisis 1.5
Aktiviti Orang Dalam NA
Volatiliti Harga -0.5
Purata Bergerak Teknikal 0.0
Osilator Teknikal -0.5
Purata 0.13

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
REGN 80 B 0.47% 18.05 2.49
ONC 37 B - 659.04 9.38
BMRN 11 B - 21.02 1.78
ALNY 48 B - 1,240.73 202.20
INCY 20 B - 17.11 4.27
RPRX 24 B 2.18% 23.09 2.72

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Large Value
% Dimiliki oleh Orang Dalam 1.89%
% Dimiliki oleh Institusi 91.98%
Julat 52 Minggu
476.49 (-36%) — 821.11 (8%)
Julat Harga Sasaran
660.00 (-12%) — 1,057.00 (-99%)
Tinggi 1,057.00 (Canaccord Genuity, 40.27%) Beli
Median 834.00 (10.68%)
Rendah 660.00 (UBS, -12.42%) Pegang
Purata 829.30 (10.05%)
Jumlah 6 Beli, 4 Pegang
Harga Purata @ Panggilan 741.09
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Truist Securities 02 Feb 2026 818.00 (8.55%) Beli 749.55
08 Jan 2026 820.00 (8.82%) Beli 801.01
Evercore ISI Group 22 Jan 2026 875.00 (16.12%) Beli 755.51
B of A Securities 07 Jan 2026 860.00 (14.13%) Beli 812.27
Morgan Stanley 12 Dec 2025 768.00 (1.92%) Pegang 741.29
03 Dec 2025 767.00 (1.78%) Pegang 723.67
Wells Fargo 10 Dec 2025 745.00 (-1.13%) Pegang 726.21
20 Nov 2025 700.00 (-7.11%) Pegang 737.00
BMO Capital 04 Dec 2025 850.00 (12.80%) Beli 722.80
Canaccord Genuity 04 Dec 2025 1,057.00 (40.27%) Beli 722.80
HSBC 24 Nov 2025 890.00 (18.11%) Beli 761.45
Scotiabank 24 Nov 2025 770.00 (2.18%) Pegang 761.45
UBS 07 Nov 2025 660.00 (-12.41%) Pegang 657.53
Papar semua

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
02 Feb 2026 Pengumuman EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases
30 Jan 2026 Pengumuman Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
21 Jan 2026 Pengumuman Nation’s Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search
02 Jan 2026 Pengumuman Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026
23 Dec 2025 Pengumuman Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma
22 Dec 2025 Pengumuman Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
07 Dec 2025 Pengumuman Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment
01 Dec 2025 Pengumuman Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)
01 Dec 2025 Pengumuman Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)
25 Nov 2025 Pengumuman Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)
19 Nov 2025 Pengumuman EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications
19 Nov 2025 Pengumuman Libtayo® (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation
13 Nov 2025 Pengumuman Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs
08 Nov 2025 Pengumuman Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet
07 Nov 2025 Pengumuman Dupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review
03 Nov 2025 Pengumuman Regeneron Announces Investor Conference Presentations
Papar semua
Hasil Dividen (DY TTM) 0.47%
Purata Hasil Dividen 1T 0.46%
Nisbah Pembayaran 2.24%
Jangkaan Pembayaran Dividen Seterusnya Mar 2026
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
20 Nov 2025 - 05 Dec 2025 0.88 Tunai
18 Aug 2025 - 03 Sep 2025 0.88 Tunai
20 May 2025 - 06 Jun 2025 0.88 Tunai
20 Feb 2025 - 20 Mar 2025 0.88 Tunai

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2025 3.52 4 0.46

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda